$11.95
−10.02%Sep 24, 2026, 11:00 UTC
Mesoblast received FDA approval to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of new commercial lots of its MSC product Ryoncil.
Source:Aug 27, 2026, 00:32 UTC
Mesoblast Limited reported financial results for the fiscal year ended June 30, 2026, with substantial revenue growth to US$120 million and gross profit of US$104 million.
Aug 17, 2026, 00:35 UTC
Mesoblast Limited completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, with 350 patients randomized and treated.
Jul 14, 2026, 00:35 UTC
Mesoblast achieved the target of 300 treated patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.
Source:Jun 25, 2026, 00:59 UTC
Mesoblast Limited drew down US$50 million from its five-year facility provided by existing shareholder and director Dr. Gregory George.
Source: